Compare AMTB & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | NEO |
|---|---|---|
| Founded | 1979 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.4M | 1.0B |
| IPO Year | 2018 | 2008 |
| Metric | AMTB | NEO |
|---|---|---|
| Price | $23.35 | $8.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $23.67 | $13.38 |
| AVG Volume (30 Days) | 234.8K | ★ 2.2M |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.29 | $10.63 |
| Revenue Next Year | $7.67 | $9.73 |
| P/E Ratio | $53.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.62 | $4.72 |
| 52 Week High | $24.38 | $13.74 |
| Indicator | AMTB | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 55.41 |
| Support Level | $21.98 | $7.50 |
| Resistance Level | $24.02 | $10.66 |
| Average True Range (ATR) | 0.63 | 0.61 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 68.97 | 48.11 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.